Despite a recent wave of contraction in the health care venture capital industry, Canaan Partners raised $600 million in its ninth fund. Granted, the bulk will go to tech investments, but about $100 million is earmarked for drug developers, and a further $100 million will go to medical device, diagnostics and health care IT firms.